BioMarin Pharmaceutical (MEX:BMRN) Cyclically Adjusted Book per Share: MXN448.75 (As of Mar. 2026)


MEX:BMRN BioMarin Pharmaceutical Inc MEX:BMRN
80 GF Score
Price MXN959.00
GF Value MXN1,498.01
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is BioMarin Pharmaceutical Cyclically Adjusted Book per Share?

BioMarin Pharmaceutical MEX:BMRN 80 Cyclically Adjusted Book per Share is MXN448.75 as of Mar. 2026. GuruFocus rates MEX:BMRN with a GF Score™ of 80/100 and a GF Value™ of MXN1,498.01 (Significantly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

BioMarin Pharmaceutical's adjusted book value per share for the three months ended in Mar. 2026 was MXN579.612. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is MXN448.75 for the trailing ten years ended in Mar. 2026.

During the past 12 months, BioMarin Pharmaceutical's average Cyclically Adjusted Book Growth Rate was 8.30% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 9.30% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 12.00% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 14.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of BioMarin Pharmaceutical was 28.40% per year. The lowest was 9.30% per year. And the median was 17.00% per year.

As of today (2026-07-06), BioMarin Pharmaceutical's current stock price is MXN959.00. BioMarin Pharmaceutical's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was MXN448.75. BioMarin Pharmaceutical's Cyclically Adjusted PB Ratio of today is 2.14.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of BioMarin Pharmaceutical was 14.10. The lowest was 2.01. And the median was 5.48.


BioMarin Pharmaceutical  (MEX:BMRN) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

BioMarin Pharmaceutical's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=959.00/448.75
=2.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of BioMarin Pharmaceutical was 14.10. The lowest was 2.01. And the median was 5.48.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


BioMarin Pharmaceutical Cyclically Adjusted Book per Share Related Terms


BioMarin Pharmaceutical Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for BioMarin Pharmaceutical's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioMarin Pharmaceutical Cyclically Adjusted Book per Share Chart

BioMarin Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 346.66 393.93 301.47 600.81 411.76

BioMarin Pharmaceutical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 497.87 467.76 453.37 411.76 448.75

MEX:BMRN vs CYTK, ARWR, TECH: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, BioMarin Pharmaceutical's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioMarin Pharmaceutical Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where BioMarin Pharmaceutical's Cyclically Adjusted PB Ratio falls into.


MEX:BMRN
80GF Score
BioMarin Pharmaceutical Inc MEX:BMRN
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioMarin Pharmaceutical Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioMarin Pharmaceutical's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=579.612/330.2130*330.2130
=579.612

Current CPI (Mar. 2026) = 330.2130.

BioMarin Pharmaceutical Quarterly Data

Book Value per Share CPI Adj_Book
201606 217.187 241.018 297.563
201609 297.954 241.428 407.526
201612 330.339 241.432 451.813
201703 300.854 243.801 407.488
201706 288.349 244.955 388.711
201709 290.951 246.819 389.256
201712 313.691 246.524 420.182
201803 288.682 249.554 381.988
201806 319.371 251.989 418.512
201809 306.482 252.439 400.906
201812 326.926 251.233 429.702
201903 318.180 254.202 413.322
201906 316.980 256.143 408.643
201909 337.937 256.759 434.615
201912 327.451 256.974 420.776
202003 420.280 258.115 537.675
202006 412.422 257.797 528.273
202009 493.435 260.280 626.013
202012 449.412 260.474 569.737
202103 465.732 264.877 580.612
202106 460.571 271.696 559.767
202109 477.867 274.310 575.254
202112 475.801 278.802 563.539
202203 472.875 287.504 543.121
202206 488.686 296.311 544.598
202209 494.531 296.808 550.189
202212 481.840 296.797 536.090
202303 447.648 301.836 489.733
202306 435.798 305.109 471.655
202309 452.899 307.789 485.895
202312 445.651 306.746 479.745
202403 443.712 312.332 469.115
202406 508.760 314.175 534.731
202409 559.376 315.301 585.831
202412 618.582 315.605 647.214
202503 618.097 319.799 638.225
202506 591.065 322.561 605.087
202509 578.376 324.800 588.015
202512 569.946 324.054 580.778
202603 579.612 330.213 579.612

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of MXN448.75 mean?
BioMarin Pharmaceutical (MEX:BMRN) has a Cyclically Adjusted Book per Share of MXN448.75 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on BioMarin Pharmaceutical and its competitors.
Is BioMarin Pharmaceutical's Cyclically Adjusted Book per Share too high?
BioMarin Pharmaceutical's current Cyclically Adjusted Book per Share is MXN448.75. Overall, BioMarin Pharmaceutical has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's Cyclically Adjusted Book per Share compare to CYTK and ARWR?
BioMarin Pharmaceutical's Cyclically Adjusted Book per Share of MXN448.75 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on BioMarin Pharmaceutical and its competitors. BioMarin Pharmaceutical's current Cyclically Adjusted Book per Share is MXN448.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, BioMarin Pharmaceutical (MEX:BMRN) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,498.01, compared to a current price of MXN959.00 — trading 36% below its estimated fair value. The current Cyclically Adjusted Book per Share is MXN448.75. BioMarin Pharmaceutical's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For BioMarin Pharmaceutical (MEX:BMRN), the current Cyclically Adjusted Book per Share is MXN448.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioMarin Pharmaceutical (MEX:BMRN) Overvalued in 2026?

Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued. The current stock price of MXN959.00 is trading 36% below its estimated GF Value™ of MXN1,498.01. GuruFocus considers BioMarin Pharmaceutical to be Significantly Undervalued.

Key valuation signals for MEX:BMRN:

  • Cyclically Adjusted Book per Share: MXN448.75
  • GF Value™: MXN1,498.01 vs. price of MXN959.00 (36% below fair value)
  • GF Score™: 80/100 with 3 warning signs

No single metric tells the full story. See the MEX:BMRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioMarin Pharmaceutical Business Description

Address 770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
80GF Score

Get the complete analysis for MEX:BMRN

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN959.00
Price
MXN1,498.01
GF Value